New member

files/tlf_content/nachrichten/2013/Logo_GeneQuine.jpgWe are pleased to welcome GeneQuine Biotherapeutics as a new member of BIO Deutschland.

GeneQuine Biotherapeutics GmbH, Hamburg

GeneQuine Biotherapeutics develops gene therapy for the treatment of osteoarthritis, the most common joint disorder in humans, and also increasingly a health problem in dogs and horses. GeneQuine is initially targeting the horse and dog markets while the long-term goal is the development of gene therapy for osteoarthritis for human use.

Go back